<DOC>
	<DOCNO>NCT00077519</DOCNO>
	<brief_summary>RATIONALE : Tipifarnib may stop growth tumor cell block enzymes necessary growth may make sensitive radiation therapy . Radiation therapy use high-energy x-rays damage tumor cell . Giving tipifarnib together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose tipifarnib give together radiation therapy treat patient unresectable locally advanced pancreatic cancer .</brief_summary>
	<brief_title>Tipifarnib Radiation Therapy Treating Patients With Unresectable Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose dose-limiting toxic effect tipifarnib administer radiotherapy patient unresectable locally advanced pancreatic cancer . Secondary - Determine 3-month clinical response patient treat regimen . OUTLINE : This multicenter , dose-escalation study tipifarnib . Patients receive oral tipifarnib twice daily week 1-8 . Patients also undergo concurrent radiotherapy daily , 5 day week , week 2-8 . Cohorts 3-6 patient receive escalate dos tipifarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 1 , 3 , 6 month . PROJECTED ACCRUAL : A total 8-18 patient accrue study within 12-15 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm pancreatic cancer Locally advance disease Unresectable disease require radiotherapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic AST ALT &lt; grade 2 elevation Bilirubin ≤ 2.0 mg/dL* NOTE : *Prior biliary stent procedure normalize bilirubin level allow Renal Creatinine ≤ 1.5 time normal Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No peripheral neuropathy ≥ grade 2 No know allergy imidazole drug , include follow : Clotrimazole Ketoconazole Miconazole Econazole Fenticonazole Isoconazole Sulconazole Tioconazole Terconazole PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior experimental standard chemotherapy recover No concurrent experimental chemotherapy Endocrine therapy Not specify Radiotherapy No prior upper abdominal radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
</DOC>